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S U M M A R Y
Non-tuberculous mycobacteria (NTM) are emerging worldwide as signiﬁcant causes of chronic
pulmonary infection, posing a number of challenges for both clinicians and researchers. While a number
of studies worldwide have described an increasing prevalence of NTM pulmonary disease over time,
population-based data are relatively sparse and subject to ascertainment bias. Furthermore, the
disease is geographically heterogeneous. While some species are commonly implicated worldwide
(Mycobacterium avium complex, Mycobacterium abscessus), others (e.g., Mycobacterium malmoense,
Mycobacterium xenopi) are regionally important. Thoracic computed tomography, microbiological
testing with identiﬁcation to the species level, and local epidemiology must all be taken into account to
accurately diagnose NTM pulmonary disease. A diagnosis of NTM pulmonary disease does not
necessarily imply that treatment is required; a patient-centered approach is essential. When treatment
is required, multidrug therapy based on appropriate susceptibility testing for the species in question
should be used. New diagnostic and therapeutic modalities are needed to optimize the management of
these complicated infections.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Pulmonary disease due to non-tuberculous mycobacteria
(NTM) has emerged as an increasingly prevalent clinical entity
in the past two to three decades. Advances in imaging and
microbiological techniques, particularly molecular techniques,
have signiﬁcantly enhanced our understanding of this disease, but
many uncertainties remain, especially in epidemiology and clinical
management. The aims of this concise and practical review are
threefold: (1) to provide an update regarding the small proportion
of the approximately 160 known species of NTM that are
commonly associated with lung disease in humans;1,2 (2) to
elucidate the clinical approach to these pulmonary infections; and
(3) to focus attention on areas of NTM pulmonary disease in which
further research is urgently required.* Corresponding author. fax: +1 919 681 7494.
E-mail address: jason.stout@dm.duke.edu (J.E. Stout).
1 Jason E. Stout and Won-Jung Koh were equal contributors to the manuscript.
http://dx.doi.org/10.1016/j.ijid.2016.03.006
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Global epidemiology
Over the past two decades, improving microbiological techni-
ques have enhanced the recovery of NTM from the respiratory
tract, and there has been a growing appreciation of their clinical
signiﬁcance. Perhaps driven by these phenomena, but also in
addition to them, there seems to have been a genuine increase in
the prevalence of pulmonary disease due to these organisms.3
Interestingly, the increase in proportion of pulmonary disease
caused by NTM seems to be associated with a simultaneous
decrease in the incidence of tuberculosis.4 However, obtaining an
accurate picture of the epidemiology of NTM disease is compro-
mised by the fact that these infections are not reportable in most of
the world. Much of the available epidemiological data on
pulmonary NTM therefore come from sentinel surveillance and
microbiology laboratory-based studies, with the attendant limita-
tions of those study designs.5 Furthermore, describing the
epidemiology of NTM pulmonary disease is complicated by several
challenges: (1) case ascertainment (e.g., patients are variably
symptomatic, and the diagnosis often depends on computedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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presence of the organism in the environment, which clouds the
signiﬁcance of a positive culture in an individual patient; (3) a
disease deﬁnition based on scant evidence; and (4) reporting of the
disease is not required or performed in many jurisdictions, resulting
in spotty population-based data. As a result of these challenges,
many authors focus on reporting disease prevalence (deﬁned as the
proportion of individuals in a given setting/region with disease
according to a standardized deﬁnition, often but not always based on
the American Thoracic Society/Infectious Diseases Society of
America (ATS/IDSA) guidelines).6 Another commonly used measure
is isolate incidence (number of individuals with NTM newly isolated
from a respiratory source during a time period, without regard to
disease status). NTM disease incidence (deﬁned as the number of
persons with a new diagnosis of NTM pulmonary disease by a
standardized deﬁnition) is rarely reported because it is challenging
to meaningfully describe given uncertainties in timing of disease
onset and variable timing and rate of ascertainment after onset.
In Ontario, Canada, the annual prevalence of NTM isolation
from respiratory specimens (without considering whether true
disease was present) has recently ranged from 14.1 to 22.2 per
100 000 population.7,8 In one study, the prevalence of disease was
estimated to be 9.8 per 100 000 in 2010.8 With the exclusion of
Mycobacterium gordonae, Mycobacterium avium complex (MAC)
was found to be the most common species both isolated from the
respiratory tract and associated with clinical lung infection,
followed by Mycobacterium xenopi and the rapidly growing
mycobacteria (RGM).
In Oregon, USA, the estimated prevalence of pulmonary NTM
disease was 8.6 per 100 000.9 A population-based study in the
same state highlighted increasing pulmonary NTM incidence from
4.8 per 100 000 in 2007 to 5.6 per 100 000 in 2012.10 In other parts
of the country, using laboratory surveillance complemented by
electronic medical record review within four health systems, the
prevalence of pulmonary disease due to NTM was estimated to be
1.4 to 6.6 per 100 000.11 In 2007, using data from ICD-9 coding
(International Classiﬁcation of Diseases ninth revision), a disease
prevalence of approximately 47 per 100 000 was observed among
adults aged 65 years in the USA, although there was quite marked
variance in the regional prevalence of NTM pulmonary disease in
different parts of the country.12
The available information from Central and South America has
been limited, with signiﬁcant potential for selection bias that calls
the generalizability of the data into question.13 The estimated
prevalence of NTM lung disease, as reported, was around 1 per
100 000 or even less. MAC was generally the most common species
isolated, followed by Mycobacterium kansasii and the RGM.13,14
In Europe, due to varying study methodologies and differences
in underlying populations studied, the reported prevalence of
isolation of NTM from respiratory specimens and the reported
prevalence of such disease have been discrepant. For example, in
the UK, Greece, and the Netherlands, NTM isolation rates of
approximately 2.9 per 100 000, 7.0 per 100 000, and 6.3 per
100 000, respectively, have been found, and the prevalence of NTM
pulmonary disease has been estimated to be 1.7 per 100 000,
0.7 per 100 000, and 1.4 per 100 000, respectively.15–17 For this
continent, recent data have also revealed marked geographic
variability in the species isolated from patients.18 MAC was
isolated more frequently in Northern Europe (44% among all NTM)
than in Southern Europe (31% of all NTM), with M. avium being the
predominant subspecies. M. xenopi was more frequently isolated in
Southern Europe (21% of all NTM isolates) than in Northern Europe
(6% only).
In Africa, there has been recent enthusiasm to search for NTM in
patients with suspected pulmonary tuberculosis.19,20 While these
studies have not categorically classiﬁed NTM lung disease, theirﬁndings suggest that a proportion of patients with suspected
tuberculosis (3.7–15%) might actually have NTM disease instead of
tuberculosis. Likewise, other studies have suggested that a
signiﬁcant proportion of patients with suspected multidrug-
resistant tuberculosis (18% in each of two studies) might have
NTM pulmonary disease instead.21,22
In Asia, there has been no population-based study regarding the
epidemiology of NTM pulmonary isolates and NTM pulmonary
disease to enable in-depth understanding of the size of the
problem. The available data come from studies undertaken in some
countries and geographical areas of Eastern Asia, notably Japan,
South Korea, India, China, Thailand, and Taiwan.23 A recent study
from Japan estimated the national prevalence of NTM lung disease
to be 33 to 65 per 100 000 in 2005, with most of the cases due to
MAC.24 The leading role of MAC in the pulmonary isolates of NTM
was also observed in most of the other countries in Eastern Asia.23
The other frequently isolated species included RGM and M.
kansasii. Mycobacterium scrofulaceum and Mycobacterium szulgai
were also occasionally found in respiratory specimens. A study
from Taiwan reported an estimated prevalence of 7.94 per
100 000 inpatients in 2008, with the disease occurring largely in
elderly subjects.25 In some Asian countries where the mainstay of
tuberculosis diagnosis is the acid-fast smear, there are concerns
that a number of patients diagnosed with tuberculosis, especially
putative drug-resistant tuberculosis, might actually have NTM
pulmonary disease (30.7% of isolates that tested resistant to
isoniazid and rifampicin and 4% of tuberculosis retreatment cases
in one study from China, similar to the African data mentioned
previously).26,27 For example, a study from China demonstrated
that 3.4% of smear-positive sputum specimens grew NTM,
primarily MAC.28
In Australia and New Zealand, there have been a few robust
population-based studies to address the epidemiology of pulmo-
nary NTM isolation and disease.29–31 The most recent data have
suggested a rising disease incidence/prevalence (it is often
challenging to distinguish the two) that reached 3 per
100 000. MAC has consistently been the most commonly isolated
pulmonary NTM species associated with pulmonary disease.29
Thus the available data, especially those derived from popula-
tion-based studies undertaken in countries in North America,
Europe, and Australia, have suggested a continuing rise in the
prevalence of pulmonary NTM isolates and NTM disease in these
continents. Studies from some countries and geographical areas in
Eastern Asia, such as Japan, South Korea, and Taiwan, have echoed
this phenomenon.5
The increasing prevalence of pulmonary disease due to NTM is
especially notable among the elderly, particularly in the context of
aging populations in many countries.11 The gender predominance
is frequently confounded by the differential prevalence of
smoking-associated lung damage between men and women.5
NTM are ubiquitous organisms found in environmental sources
that include drinking and natural water, as well as soil and dust.
Human subjects can inhale or ingest NTM in water, aerosols, or dust.
NTM are quite resistant to water disinfectants in common use, such
as chlorine.32 This resistance likely contributes to reports describing
frequent NTM detection in potable water within Australia and the
USA.32,33 The ability of NTM to persist in urban water supplies may
therefore be contributing to the increasing prevalence of pulmonary
NTM disease in many countries. The relationships between
environmental conditions, exposure, and development of disease
are poorly understood and bear further study.
3. Host susceptibility and disease pathogenesis
The early concepts of NTM in the respiratory tract described a
dichotomous scenario of colonization versus invasion.34 In all
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dichotomy and is more of a spectrum, as modeled in
Figure 1. The outcome of respiratory exposure to NTM likely
depends on a complex interplay between exposure-related factors
(particle size, number of organisms, duration) and host-related
factors (immune status, genetic background, presence of localized
or generalized lung damage). Most of this interplay is poorly
understood at present, but some recent data have begun to reveal
certain of the key factors at work.
The microbial factors and the host susceptibility factors are
discussed in the subsections below.
3.1. Clinical relevance of NTM species
The pathogenicities of the various NTM species vary widely.
Figure 2 shows the most important species that cause pulmonary
disease. These pathogens include slowly growing mycobacteria,
notably Mycobacterium malmoense, M. szulgai, M. kansasii, and M.
xenopi, as well as the RGM, especially Mycobacterium abscessus
(subsp. abscessus and bolletii).17,35 MAC account for the plurality of
pulmonary isolates as well as disease worldwide.12,24,25,35,36
Interestingly, the clinical relevance of NTM isolation from
respiratory specimens appears to vary by geographic region,
presumably due to variability in both environmental microbial
distribution and the prevalence of host risk factors.
3.2. Exposure dose of NTM
Aside from pathogenicity of the NTM species, the quantitative
exposure to mycobacteria appears to be associated with the
likelihood of progression to clinical respiratory disease.37 Howev-
er, the critical exposure dose remains unknown, and almostFigure 1. Interactions between NTM and the host that determine the clinical
outcome (NTM, non-tuberculous mycobacteria).
Figure 2. Clinically relevant species of NTM arranged according to relative
pathogenicity.certainly varies by host susceptibility. At an extreme end of the
spectrum, hot tub lung caused by NTM (which afﬂicts immuno-
competent hosts) occurs in the setting of indoor hot tubs, with
presumed exposure to large numbers of organisms due to a
combination of high organism burden in the water and concen-
tration of aerosols within closed indoor spaces.37 The relationship
between quantitative mycobacterial exposure and disease in other
settings is not well understood.
3.3. Impairment of host local defenses
A number of diseases associated with structural lung damage
have been cited as predisposing to NTM pulmonary infection.
Chronic obstructive pulmonary disease (COPD) has frequently
been associated with NTM lung disease.12,15,38,39 Pneumoconioses
such as silicosis have also been traditionally mentioned as risk
factors,40,41 although the relative importance of these conditions is
diminishing as their prevalence diminishes worldwide. Although
the available evidence is limited, there is some suggestion that
tobacco smoke and alcohol (whose mechanism may not be related
to impairment of local host defenses) may be cofactors in the
development of pulmonary involvement by NTM in the human
host.42,43
Cystic ﬁbrosis (CF) has frequently been associated with NTM
respiratory colonization and disease, and NTM infection has been
increasingly relevant in CF patients as medical advances have
prolonged the life-spans of these patients.44 NTM have been
isolated from between 4% and 32% of respiratory specimens
obtained from CF patients.45–48 Interested readers are directed to
recent references that touch on the epidemiology and transmission
of NTM in this population.49–51
In recent years, the relationship between NTM and non-CF
bronchiectasis has been further elucidated.52 Some authors have
posited that gastroesophageal reﬂux may cause bronchiectasis and
predispose to subsequent NTM pulmonary disease due to chronic
aspiration, but published associations have not been consis-
tent.52,53 There is a reciprocal relationship between bronchiectasis
and NTM pulmonary disease. NTM can cause bronchiectasis by
destroying the bronchial anatomy, and bronchiectasis can predis-
pose to NTM colonization/disease due to impaired host local
defenses.54,55 NTM pulmonary disease in bronchiectasis can also
be complicated by co-infection by other bacteria, especially
Pseudomonas aeruginosa,56 and fungi, including Aspergillus spe-
cies.57 Bronchiectasis and other forms of lung damage caused by
concurrent or prior Mycobacterium tuberculosis are also associated
with NTM infection; whether this predisposition is due to local
impairment in host defenses due to lung damage or to a common
underlying immunological defect is unknown.43,58 NTM are
frequently found in respiratory specimens from patients with M.
tuberculosis pulmonary disease, but the clinical signiﬁcance of the
NTM in this setting is unclear.59,60 In a systematic review, the
overall prevalence of NTM among patients with bronchiectasis was
9.3%. Subgroup analysis revealed that the prevalence was higher in
studies with a larger sample size, time of study at 2002 or beyond,
and Asian locations.61
A number of miscellaneous disorders associated with pulmo-
nary abnormalities have been associated with pulmonary NTM. In
patients with ciliary dyskinesia, 10% of adult patients had NTM
isolated from their sputum.62 In addition, some patients initially
thought to have idiopathic bronchiectasis were found to have CF
transmembrane conductance regulator (CFTR) gene mutations;63
whether a proportion of them might have had a ‘forme fruste’ of CF
is currently not known. Alpha-1-antitrypsin deﬁciency and
pulmonary alveolar proteinosis have also been reported as
predisposing conditions, presumably due to a combination of
anatomical abnormalities and impaired macrophage function.64,65
Figure 3. Nodular bronchiectatic form of pulmonary disease due to Mycobacterium
abscessus in a 62-year-old female patient. Chest CT shows severe bronchiectasis in
the right middle lobe and the lingular segment of the left upper lobe. Note the
multiple bilateral small nodules and tree-in-bud appearance suggesting
bronchiolitis.
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Immunosuppressed hosts are at increased risk of NTM disease,
more commonly disseminated than pulmonary.66 Immunosup-
pressive conditions associated with NTM disease include HIV
infection, hematological and lymphoproliferative malignancy,
stem cell and solid organ transplant, and inﬂammatory disorders
treated with biologicals.66 Among the anti-tumor necrosis factor
alpha (anti-TNF-a) agents, inﬂiximab and adalimumab seem to
pose a greater risk than etanercept.67 A recent population-based
study has also suggested that inhaled corticosteroids increase the
risk of NTM lung disease among patients with chronic respiratory
diseases (notably those with asthma and COPD).68 The proportion
of NTM disease involving the lungs varies widely among various
categories of immunocompromised patients, ranging from less
than 5% in patients with HIV (who primarily develop disseminated
NTM) to close to 70% among patients on biological agents such as
TNF inhibitors.66 Complicating evaluation, NTM are not infre-
quently isolated from respiratory specimens among persons with
HIV, but most of these are not associated with clinical disease. For
example, a study of patients in Southeast Asia demonstrated that
21% of 1060 HIV-infected persons evaluated had NTM isolated
from respiratory specimens, but only 19 (2%) had NTM disease,
only nine of whom had pulmonary disease (the remainder had
disseminated disease).69 An evidence-based case deﬁnition of
pulmonary NTM disease is deﬁnitely needed to clarify the
differences between colonization and disease in HIV-infected
persons.
A number of rare inherited and acquired immunodeﬁciencies
predispose to NTM infection. NTM disease afﬂicts persons with
defects in the interleukin-12/interferon-gamma axis, chronic
granulomatous disease, and common variable immunodeﬁciency;
the former two are commonly associated with disseminated
disease.65,66 There is also some evidence for an association
between MAC pulmonary disease and polymorphisms in the
natural-resistance-associated macrophage protein 1 gene.70
3.5. Host susceptibility of unknown cause
Pulmonary disease due to NTM was ﬁrst reported in elderly,
non-smoking, thin women with nodular bronchiectasis, initially
referred to (somewhat disparagingly) as ‘Lady Windermere
syndrome’.71,72 In a study of six families, clustering of pulmonary
NTM disease was noted, and the affected women similarly had low
body mass.73 In addition, 51% of patients had scoliosis, 11% pectus
excavatum, and 9% mitral valve prolapse.74 Subsequent studies
have conﬁrmed an increased prevalence of these characteristics
among both patients with NTM pulmonary disease and their
relatives.75,76 Stimulated cytokine production in the commonly
incriminated pathways of primary immunodeﬁciency was normal,
but interestingly 36% of patients had CFTR mutations. Recent data
have extended these observations, noting an increased prevalence
of mutations in genes controlling ciliary function, connective
tissue, immune function, and the CFTR in patients with pulmonary
NTM disease compared with population controls; the investigators
termed the combination of these mutations ‘Mendelian suscepti-
bility to mycobacterial disease’.77 These data strongly suggest that
pulmonary NTM in otherwise healthy persons is a manifestation of
a complex genetic disorder determined by interactions among
multiple genes, as well as environmental exposures.
4. Diagnosis
The diagnosis of NTM pulmonary disease is complicated by the
presence of the organisms in the environment and the wide
spectrum of clinical manifestations. Accurately assigning thisdiagnosis relies on a constellation of clinical features, radiographic
ﬁndings, and microbiology studies.
4.1. Symptoms and clinical features
The diagnosis of NTM pulmonary disease is frequently delayed
because the symptoms are non-speciﬁc and often occur in the
setting of pre-existing lung disease.15,55,61 Furthermore, patients
with radiographically minimal disease (e.g., solitary or few nodules)
may be entirely asymptomatic, and the bronchiectasis or nodules
that lead to the NTM diagnosis may only be detected incidentally via
imaging studies performed for another purpose.78 Historically,
signiﬁcant overlap between the symptoms of NTM pulmonary
disease and tuberculosis has been described,79 probably because
clinicians were looking for a disease resembling tuberculosis. As the
spectrum of NTM pulmonary disease has been elucidated over time,
it appears that most patients present with chronic cough, often
without symptoms such as fever or weight loss, which tend to be
present only in patients with advanced disease. 71,80,81 While
patients without pre-existing lung disease tend to have certain
morphological features (tall, thin, pectus excavatum, kyphoscoliosis,
and mitral valve prolapse),74,76 these features do not have adequate
predictive value to be diagnostically useful.
4.2. Radiographic studies
Once the diagnosis of NTM pulmonary disease is entertained,
the initial diagnostic tool is often a radiographic study. Typical
radiographic ﬁndings include a spectrum from a solitary nodule to
multiple nodules with bronchiectasis to extensive ﬁbrocavitary
disease (Figures 3 and 4). The preferred radiographic study for the
evaluation of suspected NTM pulmonary disease is a high-
resolution computed tomography (CT) scan, although recent data
suggest that thoracic magnetic resonance imaging (MRI) or
positron emission tomography (PET)-CT are emerging modalities
that may be useful in the future.82,83 CT scans are signiﬁcantly
more sensitive than plain chest radiography for the detection of
bronchiectasis and pulmonary nodules.84 The ﬁnding of nodules
associated with areas of bronchiectasis has been deemed
particularly suggestive of NTM pulmonary disease, but the positive
predictive value of this ﬁnding has ranged from 34% to 53%.85–87
Furthermore, nodules associated with bronchiectasis are much
more commonly associated with NTM pulmonary disease than
tuberculosis,88 so this ﬁnding may be helpful in sorting through the
Figure 4. Fibrocavitary form of pulmonary disease due to Mycobacterium avium in a
53-year-old male patient. Chest CT shows a large cavity in the left upper lobe. Note
the severe emphysema in both upper lobes.
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pending. Among patients with CF, the presence of at least two
characteristic ﬁndings (cystic/cavitary disease, subsegmental or
larger parenchymal consolidation, pulmonary nodules, or tree-in-
bud opacities) in patients with at least one sputum culture positive
for NTM was positively associated with meeting ATS/IDSA criteria
for NTM pulmonary disease and subsequent progression of CT
ﬁndings.89 Extensive bronchiectasis as well as bronchiectasis
involving the right middle lobe and lingula also favor NTM
pulmonary disease over tuberculosis.84 The presence of a cavity on
CT (in addition to nodules and bronchiectasis) also suggests NTM
pulmonary disease;90 in one study, 47% of patients with NTM
pulmonary disease had a cavity compared with 9% of patients with
other diagnoses.86 Immunocompromised patients are more likely
to have cavities noted on CT than immunocompetent patients, but
otherwise the radiographic ﬁndings are similar.91 Cavitary NTM
pulmonary disease is radiographically and clinically indistinguish-
able from pulmonary tuberculosis,92 which may lead to misdiag-
nosis in low-resource, tuberculosis-endemic regions.22Table 1
Microbiological tools for the diagnosis of NTM pulmonary disease
Tool Utility 
Acid-fast smear (Kinyoun or
rhodamine–auramine)
Rapid identiﬁcation of mycobacteria in 
specimen
Positive test thought to reduce the likel
organisms are contaminants
Mycobacterial culture Obtain an isolate for subsequent identiﬁ
possible susceptibility testing
Line probe assay (e.g., GenoType
Mycobacteria Direct)
Direct identiﬁcation of organisms in spu
specimens (M. avium, M. intracellulare, M
M. malmoense)
Gene sequencing (e.g., 16S, hsp, rpoB,
16S–23S ITS)
Identiﬁcation of organisms to the species
grown in culture
MALDI-TOF Identiﬁcation of organisms to the species
grown in culture
NTM, non-tuberculous mycobacteria; ITS, internal transcribed spacer; MALDI-TOF, mat4.3. Microbiological diagnosis
The microbiology laboratory is essential (but not sufﬁcient) for
the diagnosis of NTM pulmonary disease. All microbiology results
must be interpreted in the context of the patient’s clinical and
radiographic data to determine whether the patient truly has NTM
pulmonary disease. Even among patients with a positive respira-
tory culture for an NTM commonly associated with lung infection,
only 25–60% will meet criteria for NTM pulmonary dis-
ease.9,11,17,29,38,39,93 Proper microbiological diagnosis relies on a
sequence of events: (1) adequate specimen collection; (2) proper
cultivation techniques; and (3) accurate organism identiﬁcation.
For a comprehensive overview of the microbiological diagnosis of
NTM, the reader is referred to the recent review by van Ingen.94 A
brief list of microbiological tools used for the diagnosis of NTM
pulmonary disease is given in Table 1.
NTM organisms demonstrate a range of pathogenicity; some
species are usually associated with pulmonary disease when
isolated from respiratory specimens, while others are more likely
to be either transient colonizers or laboratory contaminants.95 The
discussion below therefore focuses on the situation in which an
NTM commonly associated with pulmonary disease (e.g., MAC, M.
abscessus, M. kansasii, M. xenopi, M. malmoense) is isolated from the
respiratory tract. Because all of these organisms are found in the
environment, it is often difﬁcult to determine the signiﬁcance of a
single positive culture from a respiratory specimen, particularly a
sputum specimen. For example, only 14% of Korean patients with a
single positive respiratory culture for MAC, M. kansasii, or M.
abscessus were subsequently diagnosed with NTM pulmonary
disease after a median 30 months of follow-up.96 For this reason,
the most recent ATS/IDSA guidelines suggest that at least two
positive cultures from separate expectorated sputum specimens
should be obtained to make the diagnosis of NTM pulmonary
disease.6 However, a signiﬁcant proportion of patients (particu-
larly with nodular bronchiectatic disease) will be unable to
produce a sputum specimen, so bronchoscopy and/or lung biopsy
is frequently required to obtain a diagnostic specimen.71,87,97,98
Once specimens of sufﬁcient quality and quantity are obtained
and an organism is isolated, it is essential to correctly identify the
Mycobacterium at the species level. Older techniques, such as high
performance liquid chromatography, have been superseded by
multilocus gene sequencing and matrix-assisted laser desorption/
ionization time-of-ﬂight (MALDI-TOF).94,99 Correct species identi-
ﬁcation has become increasingly important as data have come to
light regarding the relative proclivity of different species to causeComments
the
ihood that
Poor sensitivity for NTM pulmonary disease, especially nodular
bronchiectatic
Unable to distinguish mycobacterial species (morphology not
reliable)
cation and Solid and liquid media systems are complementary
Speciﬁc decontamination procedures (e.g., 5% oxalic acid) may
be useful in certain populations (e.g., cystic ﬁbrosis patients)
tum
. kansasii,
Poor sensitivity (60%)83
Not useful for rapidly growing mycobacteria
 level once Cannot discriminate down to the species level using a single
gene for some organisms, particularly some of the rapidly
growing mycobacteria
Multiple gene sequencing can discriminate species, but is
relatively costly
 level once Species identiﬁcation depends on database quality; publicly
available databases are often incomplete
rix-assisted laser desorption/ionization time-of-ﬂight.
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MAC isolated from respiratory specimens, patients with M. avium
or Mycobacterium intracellulare were signiﬁcantly (2–3-fold) more
likely to meet criteria for NTM pulmonary disease than patients
with Mycobacterium chimaera.100 Other authors have found
relative differences in the likelihood of M. avium and M.
intracellulare or even M. avium subspecies to be associated with
pulmonary disease when isolated from respiratory speci-
mens.101,102
4.4. Immunological diagnosis
Given the non-speciﬁc symptoms of NTM pulmonary disease,
the limitations of radiography, and the fact that invasive
procedures are frequently required to make the diagnosis, other
diagnostic modalities are sorely needed. Skin testing using NTM
antigens has not been useful for the diagnosis of NTM disease. Skin
test reactivity to NTM antigens is common among healthy persons,
and there is immunological cross-reactivity among NTM and
between NTM and tuberculosis.103,104 Interferon gamma release
assays have been used to diagnose tuberculosis infection, but none
are commercially available for NTM. These assays are unlikely to
be helpful for NTM diagnosis; patients with MAC pulmonary
disease actually demonstrate less interferon gamma release in
response to MAC antigens than persons without disease who have
a positive skin test response to MAC sensitin.105 Serodiagnostic
assays that detect antibodies against speciﬁc mycobacterial
antigens are increasingly being tested for MAC and M.
abscessus. One assay that has been examined uses an enzyme
immunoassay that detects IgA antibodies that bind to glycopepti-
dolipid, which is found in the MAC cell wall. The reported
sensitivity of this serodiagnostic assay for MAC pulmonary disease
ranges from 70% to 92%, depending on the population and cut-off
value studied, and there appears to be a positive association
between antibody levels and disease activity (although there is
cross-reactivity with M. abscessus as well, so the assay is not
completely speciﬁc for MAC).106–113 A second serodiagnostic test
examines IgG antibodies to mycobacterial antigen A60 as a
diagnostic for M. abscessus pulmonary disease. A60 antibody titers
were found to be relatively sensitive (86.7%) and speciﬁc (95.1%)
for M. abscessus pulmonary disease among patients with CF, and
seemed to correlate with disease activity.114 Unfortunately, A60
antigen is not speciﬁc for M. abscessus, and these antibodies may beTable 2
Conditions that predispose to NTM pulmonary disease
Category Condition 
Structural lung disease Alpha-1-antitrypsin deﬁciency
Bronchiectasis
COPD
Ciliary dyskinesia
Cystic ﬁbrosis
Pulmonary alveolar proteinosis 
Tuberculosis 
Immune deﬁciencies Chronic granulomatous disease
Common variable immunodeﬁciency
Hematological malignancy
HIV 
Interleukin-12/interferon-gamma axis defects 
Inhaled corticosteroids 
Mendelian susceptibility to mycobacterial disease 
Transplant (stem cell or solid organ)
NTM, non-tuberculous mycobacteria; COPD, chronic obstructive pulmonary disease.elevated in other mycobacterial diseases such as tuberculosis.115
While neither of these serological tests is ready for clinical use,
they represent a line of research that could signiﬁcantly advance
the diagnosis of NTM pulmonary disease (Tables 2 and 3).
5. Treatment
5.1. Treat or not
A diagnosis of NTM lung disease alone does not obligate the
immediate initiation of treatment directed against the NTM
pathogen. Instead, this decision should be based on the potential
risks and beneﬁts of a prolonged course of multiple antibiotics for
the individual patient, taking into consideration age, comorbid
medical conditions, and disease type.6,116 Patients with ﬁbroca-
vitary disease usually require immediate treatment because
cavitary disease is associated with a higher rate of mortality due
to NTM lung disease.117,118 Conversely, nodular bronchiectatic
disease tends to occur in the absence of signiﬁcant comorbidity
and often progresses slowly.119 Therefore, early treatment of mild
and indolent nodular bronchiectatic disease may not be advisable
because of the adverse effects of the long-term use of multiple
antibiotics.6,116 The decision may also be aided by molecular
analyses, because speciﬁc mycobacterial genotypes have been
shown to be predictive of disease progression or treatment
response in patients with NTM lung disease.120,121 Because
microbiological cure can be difﬁcult to achieve in a substantial
proportion of patients, other treatment goals, including improve-
ment in quality of life, may be more appropriate.122,123
Once the decision has been made to initiate treatment for NTM
lung disease, the treatment regimens should be formulated
according to established guidelines, understanding that a substan-
tial proportion of current guidelines rely upon expert opinion
rather than randomized clinical trials.124 However, adherence to
the current guidelines for treating NTM lung disease is poor, and
suboptimal or potentially harmful antibiotic regimens are
commonly prescribed in practice.125
5.2. Antibiotic therapy
5.2.1. MAC lung disease
Newer azalide/macrolide drugs such as azithromycin and
clarithromycin (subsequently both referred to as macrolides here)Comments
May be predisposing or result of NTM infection
Presence of cystic ﬁbrosis transmembrane conductance regulator gene
polymorphisms without cystic ﬁbrosis disease may predispose to NTM
infection by increasing the risk of bronchiectasis
Impaired macrophage function in this disorder may augment the risk over that
conferred by structural abnormalities
May cause bronchiectasis or other airway abnormalities; possible shared
underlying genetic vulnerability with NTM
Both of these are more likely to present with disseminated than pulmonary
disease
NTM infection relatively uncommon compared to disseminated disease; M.
kansasii and M. xenopi more likely to cause pulmonary infection
Disseminated disease more than pulmonary; genetic disorders rare; acquired
autoantibodies to interferon-gamma increasingly recognized
Local immunosuppression
Likely under-recognized underlying deﬁcit in ‘idiopathic’ NTM pulmonary
infection—complex, polygenetic disorder
Table 3
Antibiotic treatment of non-tuberculous mycobacterial lung disease
Species Recommended antibiotics Alternative antibiotics
M. avium complex Non-cavitary nodular bronchiectatic form:
Clarithromycin 1000 mg or azithromycin 500 mg TIW plus
Ethambutol 25 mg/kg TIW plus
Rifampicin 600 mg TIW
Fibrocavitary form or cavitary nodular bronchiectatic form:
Clarithromycin 1000 mg or azithromycin 250 mg daily plus
Ethambutol 15 mg/kg daily plus
Rifampicin 450–600 mg daily and/or streptomycin 10–15 mg/kg IM TIW or
amikacin 10–15 mg/kg IV TIW
Clofazimine
Moxiﬂoxacin
Linezolid
Inhaled amikacin
M. abscessus complex Amikacin 10–15 mg/kg IV daily plus
Cefoxitin up to 12 g IV or imipenem 1000–2000 mg IV daily plus
Clarithromycin 1000 mg or azithromycin 250 mg daily
Clofazimine
Linezolid
Bedaquiline
Tigecycline
Inhaled amikacin
M. kansasii Isoniazid 5 mg/kg daily up to 300 mg daily plus
Rifampicin 10 mg/kg daily up to 600 mg daily plus
Ethambutol 15 mg/kg daily
Or
Clarithromycin 1000 mg or azithromycin 250 mg daily
Rifampicin 10 mg/kg daily up to 600 mg daily plus
Ethambutol 15 mg/kg daily
TIW, three times weekly; IM, intramuscular; IV, intravenous.
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recommend three-drug macrolide-based therapy, comprising the
macrolide, rifampicin, and ethambutol, for the treatment of MAC
lung disease (Table 3).6 Streptomycin or amikacin is recommended
for patients with severe and advanced disease, especially
ﬁbrocavitary disease, although the beneﬁt of these drugs is not
entirely proven.6 Antibiotic therapy should be continued for at
least 12 months after conversion of sputum cultures from positive
to negative. In non-cavitary nodular bronchiectatic MAC lung
disease, intermittent (three times weekly) therapy has been
recommended over daily therapy because of better tolerability
noted in observational studies (Table 3).6 Intermittent therapy has
potential beneﬁts in decreasing adverse drug effects and medica-
tion costs and increasing the rate of adherence to the regi-
men.126,127 After an initiation of antibiotic therapy, sputum
microbiological analysis including semiquantitative mycobacterial
culture and CT follow-up can be used to monitor the treatment
response.128,129 Current guidelines recommend antimicrobial
susceptibility testing for the macrolides (clarithromycin) only,130
and emerging data suggest that testing for amikacin susceptibility
may be useful as well.131 Susceptibility testing for other drugs is
offered by some laboratories, but the results of such testing have
not been signiﬁcantly correlated with clinical outcomes,132 so such
testing is generally not recommended.130
Drug–drug interactions, especially between rifampicin and
clarithromycin, lead to a reduced plasma concentration of
clarithromycin and may lead to a suboptimal response to antibiotic
treatment for MAC lung disease. Low serum concentrations of
macrolides, presumably caused by drug–drug interactions, are
common in patients with MAC lung disease treated with a
macrolide and rifampicin.133,134 However, it is unclear whether
low serum concentrations of macrolides are the cause of
suboptimal treatment outcomes, and whether increasing the
macrolide dose, substitution of another drug for rifampicin, or
omitting rifampicin entirely and using a two-drug regimen
(macrolide and ethambutol) could improve treatment outcomes
of MAC lung disease.135
Treatment outcomes of MAC lung disease are unsatisfactory.
Discontinuation of treatment due to adverse drug effects is
frequent (10–30%), and the overall treatment success rate is only
40–60%.136,137 The treatment success rate is higher (70–85%) in
patients with non-cavitary nodular bronchiectatic MAC lungdisease than in those with cavitary MAC lung disease.126,127 In
some patients with non-cavitary nodular bronchiectatic MAC lung
disease with persistently positive cultures after intermittent
therapy, switching from intermittent to daily therapy may result
in a microbiological response.138
Even after successful completion of antibiotic therapy, micro-
biological recurrence (predominantly due to reinfection rather
than relapse) is relatively common (30–50%), especially in patients
with nodular bronchiectatic MAC lung disease.126,139 Treatment
success rates even in macrolide-susceptible disease are suboptimal
because of the prolonged duration of treatment, drug side effects,
and frequent reinfection. Moreover, treatment outcomes are very
poor in patients with macrolide-resistant MAC lung disease.140
Risk factors for macrolide-resistant infection include macrolide
monotherapy or combination therapy with a ﬂuoroquinolone
only;140 poor physician adherence to NTM treatment guidelines
may also be a contributory factor.125
The efﬁcacy of adding drugs to standard antibiotic treatment of
refractory MAC lung disease has not been established. Some
studies have suggested that clofazimine with a macrolide and
ethambutol may be as effective as the currently-recommended
macrolide–rifampicin–ethambutol therapy.141,142 Moxiﬂoxacin
and inhaled amikacin have been associated with microbiological
and/or symptomatic improvement in some patients who fail to
respond to standardized antibiotic treatment.143,144 However, the
role of these agents in refractory MAC lung disease is currently
unclear.145
5.2.2. Mycobacterium abscessus complex (MABC) lung disease
The treatment of MABC lung disease is problematic due to a lack
of effective antibiotics. MABC is resistant to many antibiotics and
only typically susceptible in vitro to the parenteral agents
amikacin, cefoxitin, and imipenem, as well as sometimes oral
macrolides.6 Drug susceptibility testing for agents that may have
activity is recommended,130 and limited data support an associa-
tion between the results of such testing and clinical outcomes.146
Susceptibility testing for the macrolides (using clarithromycin as
the class agent) is complicated by the presence of a functional erm
gene in many isolates; this gene codes for inducible macrolide
resistance. Testing for inducible resistance using 14-day testing in
the presence of clarithromycin is recommended at this time,130,147
although molecular tests are being explored that may obviate the
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regimen comprising two parenteral agents and a macrolide for 2 to
4 months (Table 3).6 The reported treatment success rate ranges
from 50% to 70%.146,150–153 However, these studies were retro-
spective, involved various regimens with different treatment
durations, and many patients also underwent surgery.154 There-
fore, the results cannot be generalized to all patients, and these
regimens should be applied with caution in individual patients
with MABC lung disease.
MABC lung disease can be further subdivided by causative
organism: M. abscessus subsp. abscessus (hereafter M. abscessus), M.
abscessus subsp. massiliense (hereafter M. massiliense), and M.
abscessus subsp. bolletii (hereafter M. bolletii).155,156 However, the
taxonomic status of MABC is still a subject of debate.147 It is
important to identify the exact species, because M. massiliense has
been consistently associated with a higher probability of treatment
success than other MABC organisms. For example, one study
observed sustained negative cultures in 88% of patients with M.
massiliense lung disease, compared with 25% of patients with M.
abscessus lung disease.157 Similar results have been reported in
other studies.158–161 These differences in treatment outcomes are
attributable to differential macrolide susceptibility among mem-
bers of the MABC. M. abscessus and M. bolletii display inducible
macrolide resistance conferred by the ribosomal methyl transfer-
ase erm(41) gene.162–164 In contrast, M. massiliense strains do not
show inducible resistance because of a large deletion in the
erm(41) gene that renders it non-functional.162–164 However, a
polymorphism is present at position 28 of erm(41) (T or C) in M.
abscessus.165 The majority of M. abscessus isolates are of the T28
sequevar and exhibit inducible macrolide resistance, but 7–18% are
of the C28 sequevar and susceptible to macrolides because of loss
of function of the erm(41) gene.149,166,167 Thus, both the
sequencing of the erm(41) gene of M. abscessus as well as precise
identiﬁcation of MABC are important for predicting treatment
outcomes.149,166,167
None of the commonly used MABC treatment regimens is
categorically safe, well-tolerated, and effective. The prolonged use
of parenteral amikacin is limited by nephrotoxicity and ototoxicity.
Inhaled amikacin can be considered as it might have lower toxicity
than parenteral therapy, albeit with limited efﬁcacy data.144
Clofazimine, linezolid, bedaquiline, and tigecycline show in vitro
activities against most isolates of MABC, and two-drug combina-
tions, such as clofazimine and amikacin, clofazimine and
tigecycline, and clofazimine and bedaquiline, exert synergistic
effects.168–174 Treatment with an antibiotic regimen containing
tigecycline for >1 month was shown to result in an improvement
in >60% of patients with treatment-refractory M. abscessus lung
disease. However, 90% of patients experienced adverse reactions,
largely gastrointestinal in nature.175 Bedaquiline as salvage
therapy for advanced M. abscessus lung disease was also shown
to result in improvement in six out 10 patients.176 Therefore,
experts currently believe that curative therapy is possible only in
patients with limited disease using a combination of surgical
resection and chemotherapy, particularly for M. abscessus lung
disease.177–179 Suppressive therapy using periodic parenteral
antibiotics or oral antibiotics to control symptoms and progression
of disease may be appropriate in some patients.6
5.2.3. Mycobacterium kansasii lung disease
Rifampicin is the most important drug for the treatment of M.
kansasii lung disease because it is associated with a high culture
conversion rate and low long-term relapse rate.6 The guidelines
therefore recommend a rifampicin-containing regimen in combi-
nation with isoniazid and ethambutol (Table 3).6 This regimen has
shown a high sputum culture conversion rate and a low long-term
recurrence rate. Treatment for this disease is recommended tocontinue for at least 12 months after negative sputum conversion.
Because antibiotic treatment shows an excellent outcome, surgical
resection is not recommended for this disease. Substitution of a
newer macrolide for isoniazid was recently recommended because
of the efﬁcacy of new macrolides against M. kansasii; the limited
data on this regimen are encouraging, but additional study is
needed.180,181 Fluoroquinolones may help in the presence of
rifampicin-resistant M. kansasii lung disease.182
5.2.4. Other NTM
M. xenopi infection is commonly associated with underlying
lung conditions such as COPD, and the prognosis is poor.183–185 The
recommended treatment regimen is likely a combination of
clarithromycin, ethambutol, and rifampicin, with or without an
initial course of streptomycin. Moxiﬂoxacin can be substituted for
one of the recommended drugs, as guided by drug susceptibility
testing.6,186 Regarding the treatment of M. malmoense lung disease,
previous studies have suggested combination therapy of isoniazid,
rifampicin, and ethambutol, with or without ﬂuoroquinolones/
macrolides.187,188 Most M. szulgai isolates are susceptible in vitro
to many anti-tuberculosis drugs. Treatment with isoniazid,
rifampicin, and ethambutol or macrolide, rifampicin, and etham-
butol may lead to favorable outcomes without microbiological
recurrence.189–191 The optimal antibiotic regimen for Mycobacte-
rium simiae lung disease is unknown. Although combination
therapy with clarithromycin, ethambutol, and rifampicin is
sometimes recommended,6 treatment outcomes in M. simiae lung
disease are typically poor due to high rates of resistance to these
drugs and a likely lack of rifampicin–ethambutol synergy.192–194 A
treatment regimen including both a macrolide and moxiﬂoxacin,
and one or two additional drugs based on drug susceptibility test
results, or adding clofazimine to an amikacin-containing regimen,
has been suggested recently due to their synergistic activity.169,193
M. scrofulaceum lung disease is associated with old tuberculosis
scarring and silicosis,195 and there appears to be no optimal
treatment regimen. Currently, rifampicin, ethambutol, isoniazid,
and perhaps macrolides/ﬂuoroquinolones, can be considered with
some guidance from drug susceptibility testing, similar to the
situation for members of the M. simiae complex.6,196
5.3. Surgical therapy
Because the success rates of combination antibiotic treatment
for NTM lung disease are unsatisfactory, adjuvant surgical
resection could be considered in selected patients with localized
refractory NTM lung disease who can tolerate the procedure.
Although the sputum culture conversion rate among patients who
undergo resection is >90% with acceptable morbidity and
mortality rates in many reported series, postoperative complica-
tions including bronchopleural ﬁstula have been reported,
especially in patients with ﬁbrocavitary NTM pulmonary dis-
ease.197–199 The optimal selection criteria, timing, and duration of
postoperative medical therapy require further evaluation.
6. Epilogue
There remain considerable gaps in our knowledge regarding the
management of NTM lung disease. Microbiological eradication
using currently available antibiotic regimens is difﬁcult and
microbiological recurrence is common even after successful
completion of treatment of NTM lung disease. The role of drug
susceptibility testing and therapeutic drug monitoring has not
been fully established. Discrepancies between in vitro drug
susceptibility and clinical outcomes and the lack of pharmacoki-
netic and pharmacodynamic indices for the currently used drugs
make the selection of the optimal antibiotic and determination of
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antibiotic resistance to commonly used drugs for NTM lung
disease, such as macrolides, is a challenging problem.202,203 There
are currently only limited data on the efﬁcacy of repurposed and
new agents. Perhaps most importantly, our understanding of
patient-relevant outcomes for the treatment of NTM pulmonary
disease is still quite premature. Given that survival among patients
with NTM pulmonary disease is primarily determined by
underlying comorbidities, rather than by the NTM disease or its
treatment,117,118,204 studies focusing on the impact of NTM
pulmonary disease and its treatment on patient function and
quality of life are of paramount importance.122 Such data are
particularly relevant given that preliminary work suggests weak
associations between traditional ‘hard’ endpoints such as micro-
biological culture conversion and radiographic improvement and
patient-centered endpoints such as quality of life.123,203 To this
end, quality clinical trials focused on such patient-centered
outcomes are needed to delineate new regimens or approaches
in the management of NTM lung diseases.
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